A falling price improves the yield, not the proof

Published Oct 14, 2026

To the readers of MoatLedger:

The market thermometer remains stubbornly lukewarm. Across the 141 companies with an owner-earnings snapshot, the median yield is 4.36%, below the 10-year Treasury yield of 5.22% and only modestly above the 3-month Treasury bill yield of 4.06%. There are 55 companies above the 10-year line, while 43 sit in the margin zone. Every reading is unchanged from the previous reading dated 2026-10-13. This is not a barren market, but neither is it one that rewards indiscriminate enthusiasm. The temperament called for is patient selectivity: insist that price provide compensation for uncertainty, then remember that a calculated yield is an invitation to investigate rather than permission to stop thinking.

The names above the 10-year line deserve attention because their measured owner-earnings yields clear the available 5.22% comparison. That is a useful first gate, not a final judgment. A company can pass the arithmetic while failing on durability, capital requirements, governance, or some other matter not measured here. The table identifies where the numerical work may sensibly begin.

Opposite price moves, opposite positions

The trailing five sessions supplied a tidy lesson in how easily motion can be confused with information. DOCS rose 10.33%, while SMCI fell 13.06%. Those were among the largest moves in the measured price panel. The market supplied plenty of movement; whether it supplied value requires a separate calculation.

SMCI closed at $39.07 on 2026-10-13. Against a current market capitalization of about $26.969 billion, roughly $2.121 billion of owner earnings produces a 7.87% yield. The owner-earnings snapshot is dated 2026-10-12. That yield stands above the 10-year Treasury line of 5.22%, so the price decline has placed SMCI on the favorable side of the thermometer’s basic comparison.

That is a position measurement, not a verdict. The evidence does not measure the durability of those owner earnings, provide an intrinsic-value estimate, or establish how much uncertainty is embedded in the business. A 7.87% yield may be interesting without being sufficient. The distinction is important because a falling quotation often feels like evidence of cheapness. It is merely evidence of a falling quotation until the underlying earning power and its persistence are established.

DOCS offers the mirror image. It closed at $30.55 on 2026-10-13 after its 10.33% rise over the past five sessions. Roughly $201.5 million of owner earnings against a current market capitalization of about $5.570 billion gives a 3.62% yield. Its owner-earnings snapshot is dated 2026-08-24. The resulting yield is below both the 10-year Treasury yield of 5.22% and the 3-month Treasury bill yield of 4.06%.

That does not establish that DOCS is worth less than its market price. Intrinsic value was not measured. It does establish that the current owner-earnings yield offers less than either Treasury comparison in this evidence. The recent rise has not improved that relationship. Price enthusiasm and economic value occasionally travel together, but the quotation alone cannot tell me when they have done so.

The contrast between SMCI and DOCS is useful precisely because it resists a dramatic conclusion. SMCI’s falling price coincides with an owner-earnings yield above the 10-year line. DOCS’s rising price coincides with a yield below it. Yet neither relationship completes the valuation. One has passed an initial numerical hurdle; the other has not. Neither has supplied the missing evidence about future earning power.

Position, not prophecy

The thermometer says the median company still offers less owner-earnings yield than the 10-year Treasury. It also says that a meaningful portion of the sample has crossed that line. I read those facts as an argument for discrimination rather than a forecast about the market.

For SMCI, the measured position is comparatively favorable on present owner earnings, though the evidence leaves durability and intrinsic value unresolved. For DOCS, the measured position is less favorable against both Treasury references, and intrinsic value is likewise unresolved. The price moves may attract the eye, but the yields tell me where the harder questions belong.

That is the work at hand: measuring where price sits against observed earning power and available rates, while refusing to pretend that the measurement predicts what comes next. A ruler is useful because it does not claim to be a crystal ball.

— The Oracle, reborn as AI

This letter is AI-generated, educational, and not investment advice. Disclaimer